Content uploaded by Lavanya Prathap
Author content
All content in this area was uploaded by Lavanya Prathap on Nov 20, 2017
Content may be subject to copyright.
1
--
Original Article:
Association of Quantitative and Qualitative Dermatoglyphic Variable and DNA
Polymorphism in Female Breast Cancer Population
Authors
Lavanya Prathap, Adjunct Assistant Professor, Department of Biomedical Sciences, Gulf Medical University, Ajman, UAE,
Vijayakumar Jagadeesan, Professor, Saveetha Medical College, Saveetha University, Chennai, India,
Prathap Suganthirababu, Assistant Professor, College of Allied Health Sciences. Gulf Medical University, Ajman, UAE,
Deepthi Ganesan, Assistant Professor, Saveetha College of Physiotherapy, Saveetha University, Chennai, India.
Corresponding Address
Dr.Lavanya Prathap,
5/5 Manali New Town,
Chennai-600103.
Email: lavanya.anatomist@gmail.com
Citation
Prathap L, Jagadeesan V, Suganthirababu, P, Ganesh D. Association of Quantitative and Qualitative Dermatoglyphic Variable and
DNA Polymorphism in Female Breast Cancer Population. Online J Health Allied Scs. 2017;16(2):2. Available at
URL:http://www.ojhas.org/issue62/2017-2-2.html
Submitted: Feb 10, 2017; Revised: Apr 4, 2017; Accepted: July 13, 2017; Published: July 30, 2017
Abstract: Objective: To investigate the association between
dermatoglyphics and the DNA repair genetic variants in
female breast carcinoma. Methodology: The distinct
dermatoglyphic variables include ≥ six whorls, Finger ridge
counts, A-B Ridge Count, ATD angle and Pattern intensity
Index are analyzed for its association with the DNA repair
variants namely XRCC1 Arg194Trp, XRCC3Thr241Met,
ERCC4Arg 415Gln, and ERCC5 Asp1104His. The statistical
procedure used to analyze the frequency of association is odds
ratio and relative risk ratio. Result: The results suggests that
the relative risk is about 2 to 4 times with statistical
significance for breast cancer and high risk group for the genes
XRCC1 Arg194Trp, ERCC4 Arg 415 Gln, ERCC5
Asp1104His in their dominant model in both breast cancer and
high risk group for six or more whorls, Pattern Intensity Index,
A-B RC. Conclusion: It can be suggested that dermal ridges
can be used as an effective biomarker of genomic instability in
breast cancer.
Key Words: Dermatoglyphics, DNA repair gene, single
nucleotide polymorphism, breast cancer, genetic instability
Introduction:
Breast Cancer is a complex multi-factorial disease. The
distribution of the status varies between populations based on
their life style, environment, socio-economic status, awareness
and quality of medical care. The Breast cancer incidence peaks
in Asia among women in their 4th decade of life. In United
States and Europe, it peaks among women in their 6th decade.
Cancer statistics in Indian women is 25-30 and the age
adjusted rate is 30-35 new cases per 100,000 women per
year.(1-3) The causative factor of breast cancer cannot be
definitely defined still. It involves the combination of both
genetic and environmental factor. More number of genes are
reported to be responsible for breast cancer. It becomes a very
complex, costly and time consuming process to perform
genetic testing and it involves follow up too. On the other hand
research on dermal ridge patterns are becoming evident as it
has got specific association with breast cancer. Dermal ridge
patterns are said to act as a biomarker of our gene. It reflects
the DNA pattern and the genetic instability. The different
variables of dermal ridges in different areas of palm reflect the
condition of specific gene.(4-7)
Methodology:
The study is being conducted among 150 females in three
groups, each comprising of 50, carried out in the Department
of Anatomy, ACS Medical College and Hospitals, Dr.MGR
Educational and Research Institute, University, Department of
Industrial Biotechnology, Dr. MGR Engineering and Research
Institute, Dr.MGR Educational and Research Institute
University, Tamilnadu, India, and Saveetha Medical College
and Hospital, Saveetha University, Chennai, Tamilnadu,
India. The participants are age matched between 35-60 years.
The study commenced after getting approval from the
Institutional Human Ethical Committee, Saveetha University -
IHEC No-06/10/2012, Dated -09th October 2012. Chennai,
Tamilnadu. The participants are given detailed explanation
about the procedure and their co-operation and willingness is
obtained with an informed consent.
The participants are grouped based on selection criteria. Group
I includes females diagnosed histopathologically for breast
cancer as their primary site of carcinoma. Group II includes
females who are a categorized as high risk for breast cancer
based on their family history for breast cancer (mother, sister
or daughter) or any two criteria based on their endogenous
exposure to estrogen which includes Menstrual history (early
menarche below 12 years, late menopause above 50 years)
Parity status (First Full Term Pregnancy – FFTP above 30
years of age, Nulliparity), Personal history of fibro-adenoma,
obesity, Hormone Replacement Therapy (HRT). Group III
includes normal healthy females. The exclusion criteria for
group I &II includes breast cancer developed as secondaries
from primary site of origin elsewhere, population exposed to
chemotherapy or radiation therapy, population affected with
any other major health problem, Male participants and those
who do not possess proper visible dermal ridges due to their
occupation. The exclusion criteria for group III includes
personal or family history of breast cancer, Personal or family
This work is licensed under a
Creative Commons Attribution-
No Derivative Works 2.5 India License
Online Journal of Health and Allied Sciences
Peer Reviewed, Open Access, Free Online Journal
Published Quarterly : Mangalore, South India : ISSN 0972-5997
Volume 16, Issue 2; Apr-Jun 2017
2
history of non-malignant tumor, population exposed to
chemotherapy or radiation therapy, population affected with
any other major health problem, Male participants, and those
who do not possess proper visible dermal ridges due to their
occupation.
The data for dermatoglyphic analysis are collected using
digital photography and the different variables are analyzed
using computer. After the detailed analysis of various dermal
ridge patterns, the distinctive dermatoglyphic variables are
used as an outcome measure to assess its association with
single nucleotide polymorphism (SNP) status of four DNA
repair genes. The DNA repair variants namely XRCC1
Arg194Trp, XRCC3Thr241Met, ERCC4Arg 415Gln, ERCC5
Asp1104His are analyzed for the study population. The data
collection procedure includes collection of 3ml of peripheral
blood in EDTA coated test tubes through venipucture. The
procedure includes extraction of DNA, followed by
amplification of specific gene segments using Polymerase
Chain Reaction and identification of polymorphism using
Restriction Fragment Length Polymorphism. The frequency of
appearance of all genotypes namely homozygous wild,
heterozygous mutant and homozygous mutant genotypes are
assessed and the frequency of breast cancer and high risk
population are compared with control group. The distinct
dermal ridge variables include ≥ six whorls, Mean Finger
Ridge Count (MFRC), Total Finger Ridge Count (TFRC), A-
B Ridge Count, ATD angle, Pattern Intensity Index-Digital
(PII-D). All the dermal ridge parameter is assessed
individually for its association with all the four SNPs. The
frequencies of appearance of all the genotype for each
distinctive dermal ridge variables are analyzed.
Data Analysis:
The statistical procedure used to analyze the frequency of
association between Dermatoglyphic Pattern and Variant
Allele of DNA Repair Gene is odds ratio, relative risk and the
level of significance using P- value.
Results:
The distinct dermatoglyphic parameters are six and more than
Six Whorls, Mean Finger Ridge Count (MFRC <12.6), Total
Finger Ridge Count (TFRC<126), A-B Ridge count (<34.8),
ATD Angle (<43°), Digital Pattern Intensity Index (PII-
D>12.5). Dermatoglyphic variables Six and more than six
Whorls, Mean Finger Ridge Count (MFRC<12.6), A-B Ridge
count (<34.8) and Digital Pattern Intensity Index (PII-D
>12.5) are associated with significant difference p<0.05 with
XRCC1 Arg194Trp, ERCC4 Arg 415 Gln, ERCC5
Asp1104His in their homozygous wild and heterozygous
mutant type. ERCC5 Asp1104His is associated with
significant difference in their homozygous mutant type. Total
Finger Ridge Count (TFRC<126) is associated with
significant difference with all the four DNA repair genes in
their homozygous wild and heterozygous mutant type. ATD
Angle (<43°) is associated significantly with XRCC3 Thr241
Met in their homozygous wild, heterozygous mutant type and
also homozygous mutant type (p<0.05) (Table 1 & Fig 1).
Figure 1: Dermatoglyphic Pattern Frequency Association
with Variant Allele of DNA Repair Gene – heterozygous
mutant. (*Statistically significant)
On analyzing the risk ratio of breast cancer and high risk group
for the dominant pattern of inheritance, it presented the
relative risk for six or more whorls around three times for
both high risk and breast cancer group respectively for
genotypes XRCC1 Arg 194 Trp, ERCC4 Arg 415 Gln, ERCC5
Asp 1104 His with statistically significant difference. The
relative risk of MFRC is around 2, even though the risk is
presented to be 2 it is not statistically significant. The RR for
PII-D is >1 for XRCC1 Arg 194 Trp and ERCC5 Asp 1104
His in breast cancer group and RR is 2 for XRCC1 Arg 194
Trp, ERCC4 Arg 415 Gln, ERCC5 Asp 1104 in high risk
group with statistical significance. The RR for A-B RC is 2 for
XRCC1 Arg 194 Trp and 3 for ERCC4 Arg 415 Gln in breast
cancer group and 2 for ERCC5 Asp 1104 His in high risk
group with statistical significance (Table-2).
Figures 2,3,4: Dermatoglyphic Patterns - Whorl, Arch and Ulnar Loop
2
Table 1: Association between Dermatoglyphics and Polymorphism of DNA Repair Gene.
Gene &Codon
Genotype
Negative and Positive pattern Frequency
≥6 Whorls
N=63(42)
MFRC <12.6,
N= 105(70%)
TFRC,
<126, N=100(66)
A-B ridge count
<34.8- n=67(45)
ATD angle <43°,
n= 123(82%)
PII- D->12.5
N=78(52)
XRCC1
R194W
R/R
OR (CI at 95%)
60.43
(7.90-462.0)
4.14
(1.18 – 14.5)
3.43
(1.11-0.55)
7.62
(2.70-21.5)
15.6
(0.9-255.2)
35.50
(4.6-270.0)
P Value
0.0001
0.03
0.03
0.0001
0.06
0.0006
R/W
OR (CI at 95%)
0.017
(0.002-0.13)
0.25
(0.07-0.89)
0.30
(0.10-0.95)
0.14
(0.04-0.39)
0.06
(0.003-1.1)
0.02
(0.003-0.2)
P Value
0.0001
0.03
0.04
0.0002
0.06
0.0007
W/W
OR (CI at 95%)
0.2
(0.009-5.94)
0.76
(0.03-19.15)
0.65
(0.02-16.4)
0.26
(0.01-6.62)
1.48
(0.05-37.4)
0.35
(0.01-8.88)
P Value
0.3819
0.87
0.78
0.41
0.81
0.35
XRCC3
T241W
T/T
OR (CI at 95%)
1.77
(0.7-4.06)
0.72
(0.30-1.72)
0.28
(0.12-0.67)
1.09
(0.47-2.48)
0.18
(0.07-0.47)
0.90
(0.39-2.06)
P Value
0.17
0.46
0.004
0.83
0.0004
0.81
T/M
OR (CI at 95%)
0.55
(0.23-1.34)
1.50
(0.60-3.73)
2.84
(1.16-6.92)
0.94
(0.39-2.27)
3.60
(1.37-9.45)
1.10
(0.45-2.63)
P Value
0.191
0.38
0.02
0.90
0.0009
0.81
M/M
OR (CI at 95%)
0.7176
(0.09-5.23)
0.77
(0.07-7.63)
6.31
(0.64-62.3)
0.80
(0.11-5.8)
15.2
(1.5-152.8)
1.08
(0.14-7.91)
P Value
0.74
0.82
0.11
0.82
0.02
0.83
ERCC4
R415Q
R/R
OR (CI at 95%)
8.571
(3.4-21.5)
5.86
(1.69-20.35)
24.1
(3.1-182.5)
16.01
(5.25-48.7)
0.63
(0.25-1.61)
6.16
(2.3-16.01)
P Value
<0.0001
0.005
0.002
<0.0001
0.34
0.94
R/Q
OR (CI at 95%)
0.1522
(0.06-0.38)
0.20
(0.05-0.72)
0.05
(0.006-0.3)
0.07
(0.02-0.24)
1.52
(0.57-4.02)
0.20
(0.07-0.53)
P Value
<0.0001
0.01
0.003
<0.0001
0.39
0.0002
Q/Q
OR (CI at 95%)
0.075
(0.004-1.46)
0.24
(0.01-4.70)
0.21
(0.01-4.02)
0.08
(0.004-1.5)
1.53
(0.15-15.3)
0.11
(0.006-2.1)
P Value
0.08
0.35
0.30
0.09
0.71
0.14
ERCC5
D1104H
D/D
OR (CI at 95%)
22.868
(9.254-56.5)
8.63
(2.88-25.83)
24.00
(5.5-104.1)
72.59
(20.3-259)
18.41
(2.4-140.1)
15.81
(6.11-40.8)
P Value
0.0001
0.0001
<0.0001
<0.0001
0.004
<0.0001
D/H
OR (CI at 95%)
0.0623
(0.02-0.15)
0.14
(0.04-0.42)
0.05
(0.01-0.22)
0.01
(.005-0.06)
0.06
(0.008-0.4)
0.08
(0.03-0.21)
P Value
<0.0001
0.0005
0.0001
<0.0001
0.008
<0.0001
H/H
OR (CI at 95%)
0.06
(0.003-1.12)
0.20
(0.01-3.70)
0.17
(0.009-3.1)
0.06
(0.003-1.2)
0.3
(0.02-7.29)
0.09
(0.005-1.6)
P Value
0.05
0.20
0.23
0.07
0.53
0.10
Table 2: Risk Ratio and Odds Ratio of Polymorphism (Dominant Model) In Breast Cancer and High Risk Population with Distinct Dermatoglyphic
Pattern.
Dermatoglyphic Variables
Groups
RR/OR/ P -value
XRCC1
Arg194Trp
XRCC3
Thr214Met
ERCC4
Arg415Gln
ERCC5
Asp1104His
≥ six whorls
Breast cancer
RR (95% CI)
3(1.89-4.76)
1(0.45-2.02)
3(1.51-4.05)
3(1.60-4.21)
OR(95% CI)
∞
1(0.20-4.12)
13(2.48-66.16)
13(3.68-45.8)
P Value
<0.0001
1
0.0007
<0.0001
High Risk
RR(95% CI)
3(1.87-4.34)
1(0.72-2.45)
3(1.46-4.31)
3(1.74-6.11)
OR(95% CI)
∞
2(0.44-7.5)
9.06(2.13-38.49)
15(3.51-66.84)
P value
<0.0001
0.48
0.002
<0.0001
MFRC <12.6
Breast cancer
RR(95% CI)
2(1.01-1.32)
1(0.53-1.21)
1(1.01-1.34)
1.17(0.96-1.51)
OR(95% CI)
∞
0.23(0.03-1.67)
∞
7(0.74-70.51)
P Value
0.30
0.17
0.16
0.14
High risk
RR(95% CI)
1(0.84-1.40)
1(0.67-1.31)
1(0.72-1.25)
1.22(0.98-1.52)
OR(95% CI)
1(0.20-17.5)
1(0.11-4.16)
1(0.15-3.60)
5(0.59-46.5)
P Value
0.67
1
1
0.13
PII>12.5
Breast cancer
RR(95% CI)
1.3(1.13-1.69)
1(0.43-1.30)
1(0.76-1.36)
1.5(1.07-2.25)
OR(95% CI)
∞
0.33(0.06-1.72)
1(0.24-5.06)
9(1.72-50.61)
P Value
0.04
0.33
1
0.008
High risk
RR(95% CI)
2(1.19-2.45)
1(0.56-1.76)
2(1.24-2.77)
2(1.05-2.57)
OR(95% CI)
8(0.94-70.4)
1(0.24-4.11)
8(1.54-40.09)
4(1.08-14.80)
P Value
0.03
1
0.01
0.04
A-B RC <34.8
Breast cancer
RR(95% CI)
2(1.32-3.19)
1(0.31-2.08)
3(1.65-4.26)
∞
OR(95% CI)
8(1.63-43.17)
0.7(0.15-3.23)
27(3.22-234)
∞
P Value
0.0009
0.71
0.0001
3.75
High risk
RR(95% CI)
1(0.91-1.80)
1(0.46-1.36)
1.3(0.99-1.84)
2(1.32-2.59)
OR(95% CI)
3(0.51-14)
0.5(0.11-2.13)
4(0.74-19.6)
∞
P Value
0.30
0.43
0.17
0.0006
RR – Risk ratio, OR- Odds ratio
1
Figure 5: Finger Ridge Count
Figure 6: ATD Angle
Figure 7: A-B Ridge Count
Discussion:
Of all the genes involved in the process of carcinogenesis,
DNA Repair genes forms the corner stone. Instability of DNA
Repair gene leads to instability of proto-oncogene, oncogene,
tumor suppressor gene and suicidal genes. It has got specific
pathways namely NER,BER,HR,DSB which takes
important role in repairing the damages caused by aging,
exposure to oxidative stress etc., The DNA Repair Gene is the
back bone of all the other genes. The four SNP are found to be
reported in number of studies to be associated with breast
cancer (8-11), which is in agreement with the present study. In
observation, three SNPs namely XRCC1 Arg194Trp, ERCC4
Arg 415 Gln, ERCC5 Asp1104His reported to have significant
associated with breast cancer and high risk in the present
study. The Results of XRCC3 Thr241Met is inconclusive.
On Observation dermatoglyphic variables six and more than
six whorls, mean finger ridge count (MFRC<12.6), A-B ridge
count (<34.8) and digital pattern intensity index (PII-D >12.5)
are observed to be associated in increased frequency with the
variant allele of DNA repair gene single nucleotide
polymorphism rs1799782, rs1800067 and rs17655 in their
heterozygous mutant type and with rs17655 in their
homozygous mutant type also. Total finger ridge count
(TFRC<126) is observed to be associated in increased
frequency with the variant allele of DNA repair gene Single
nucleotide polymorphism rs1799782, rs861539, rs1800067
and rs17655 in their heterozygous mutant type alone. ATD
Angle (<43°) observed to be associated in increased frequency
with the variant allele of DNA repair gene single nucleotide
polymorphism rs861539 in their heterozygous mutant type
and homozygous mutant type and rs17655 in their hetero
mutant type. The relative risk is about 2 to 4 times with
statistical significance for breast cancer and high risk group for
the genes XRCC1 Arg194Trp, ERCC4 Arg 415 Gln, ERCC5
Asp1104His in their dominant model in both breast cancer and
high risk group for the variables six or more whorls, PII-D, A-
B RC.
The study of dermal ridge patterns on the skin of palm of hand
and sole of foot play a vital role in the field of forensic,
anthropology, criminology and medicine.(12) Because of less
2
number of researches in dermatoglyphics, its role in medical
field is very limited. Importance of dermal ridges is still given
only in the field of forensic, person identity etc,. The hidden
secrets of dermal ridges of skin need to be broken in the field
of medicine to be used as a useful, powerful, sensitive, and
cost-effective, less time consuming screening, diagnostic
procedure. Number of studies reported the association of
dermal ridge pattern and breast cancer.(13-18) But still the
concept of development of dermal ridges and its genetic base
remains unclear. Similarly number of studies reported the
genetic basis of breast cancer.(8,10,11) As specific
dermatoglyphic parameters are related to breast cancer and
both breast cancer and the dermal ridges have the genetic base,
it is suggested that there can be a common genetic basis for
distinct dermal ridge in relation to breast cancer. Breast cancer
is expressed only after getting exposed to inducing factors, but
dermal ridges are developed in the womb itself and the status
of gene is expressed in the dermal ridges which remains
unchanged forever. So even before the process of
carcinogenesis begins or the appearance of visible tumor one
can be screened for breast cancer risk which aids for effective
preventive measures and early therapies and improves the
quality of life. To investigate this hypothesis the association of
distinct dermal ridges and DNA repair gene SNPs are observed
for the first time.
Conclusion
The results of the present study confirmed the involvement of
XRCC1 Arg194Trp, ERCC4 Arg 415 Gln, and ERCC5
Asp1104His in breast cancer particularly in population with
distinct dermal ridge pattern. It can be suggested the dermal
ridges can be used as an effective biomarker of genomic
instability in breast cancer. Thus the study aimed to investigate
the genetic background of association between breast cancer
and distinct palm ridge pattern. It can be suggested that the
dermal ridge pattern can be used as a biomarker of specific
DNA Repair gene polymorphism that serves as a screening
procedure.
Acknowledgments: We would like to deliver sincere thanks
to Dr. MGR Educational & Research Institute University and
Saveetha University, Tamilnadu, India.
Conflict of interest: Nil
References
1. McPheron K, Steel CM, JM Dixon. BAC of Breast
Diseases. Breast cancer – epidemiology, risk factors and
genetics. BMJ. 2000;321(7261):624-628.
2. Gabriel N, Hortobagyi J. The Global Breast cancer
Burden: Variations in Epidemiology and survival.
Clinical Breast Cancer. 2005;6(5):391-401.
3. Mense SM, Fabrizio R, Ahima B et al. Estrogen Induced
Breast Cancer-Estrogen Induced Breast Cancer:
Alterations in Breast Morphology andn Oxidative stress
as a function of estrogen exposure. Toxicology and
Applied Pharmacology. 2008;232(1):78-85.
4. Hortobagyi GN, Garza SJ, Pritchard K et al. The global
breast cancer burden: variations in epidemiology and
survival. Clin. Breast Cancer. 2005;6(5):391-401.
5. Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung
PS. Spectrum of breast cancer in Asian women. World J
Surg. 2007;31(5):1031-1040.
6. Anderson BO, Jakesz R. Breast cancer issues in
developing countries; an overview of the breast health
global initiative. World J Surg. 2008;32(12):2578-2585.
7. Porter P. Westernizing women’s risk? Breast cancer in
lower-income countries. N Engl. J Med. 2008;358:153-
156.
8. Kumar R, Hoglund L, Zhao C, Forsti A, Snellman E,
Hemminki K. Single nucleotide polymorphisms in the
XPG gene: determination of role in DNA repair and
breast cancer risk. Int J Cancer.2003;103(5):671-675.
9. Sangrajrang S, Schmezer P, Burkholder I, Bottettai,
Bartsch H, Popanda O. The XRCC3 thr 241 met
polymorphism and breast cancer risk: a case control
study in a Thai population. Biomarkers. 2007;12(5):523-
532.
10. Jorgensen TJ, HelzlsouerKJ,Clipp SC, Bolten JH, Crum
RM, Visvanathan K. DNA Repair gene variants
associated with Benign Breast Disease in High Cancer
risk women. Cancer Epidemiol Biomarkers Prev.
2009;18(1):346-50.
11. Ming-Shiean H, Yu JC, Wang HW,Chen ST, Hsiung
CN, Ding SL. Synergistic effects of polymorphisms in
DNA repair genes and endogenous estrogen exposure on
female breast cancer risk. Ann Surg Oncol. 2010:17:760-
771.
12. Blanka S, Milton A. Dermatoglyphics in medical
disorders. Springer-Verlag; New York. 1976, NY, 1-33.
13. Sakineh A, Nahid E, Nasrin D, Vaez Z. Study of
Dermatoglyphic pattern of hand in women with breast
cancer. Pak J Med Sci. 2006;22(1):18-22.
14. Chintamani, Khandelwal R, Mittal A, Saijanani S, Tuteja
A, Bansal A, Bhatnagar D, Saxena S. Qualitative and
Quantitative deramtoglyphic traits in patients with breast
cancer: a prospective study, BMC Cancer. 2007;7:44.
15. Sridevi NS, Silvia CRWD, Kulkarni R, Seshagiri C.
Palmar dermatolglyphics in carcinoma breast of Indian
women. Romanian Journal of Morphology and
Embryology. 2010;51(3):547-550.
16. Kavitha P, Geetha, Singh J, Agarwal SK. Analysis of
qualitative and quantitative dermatoglyphic traits in
breast cancer patients association with ABO Blood
group. Asian J. Pharm Health Science. 2013;3(2):583-
585.
17. Sukre SB, Laeeque M, Mahajan A, Shewale SN.
Dermatoglyphics in the identification of women either
with or at risk of breast cancer. International Journal of
Basic Medical Science. 2012;3(5):160.
18. Aparjita R, Viswawas J, Ramnath T et al. A Cross-
Sectional study on Palmar dermatoglyphics in relation to
carcinoma Breast patients. Journal of Clinical and
Diagnostic Research. 2013;7(4):609-612.